Evidence map›Paper›PMID 42262639›Full record

ArticleOncology and therapy2026

Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

Patrick Squires, Ke Meng, Xiaohan Hu, Vladimir Turzhitsky, Yu-Han Kao, Jennifer Stuart, Chethan Ramamurthy, Haojie Li, Ronac Mamtani

Abstract readPublished Erratum
In one paragraph

Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Patrick SquiresMerck & Co., Inc., Rahway, NJ, USA. patrick.squires@merck.com.ORCID http://orcid.org/0009-0003-6819-5764
Ke MengMerck & Co., Inc., Rahway, NJ, USA.
Xiaohan HuMerck & Co., Inc., Rahway, NJ, USA.ORCID http://orcid.org/0000-0002-1263-5295
Vladimir TurzhitskyMerck & Co., Inc., Rahway, NJ, USA.ORCID http://orcid.org/0000-0001-8610-8730
Yu-Han KaoMerck & Co., Inc., Rahway, NJ, USA.ORCID http://orcid.org/0000-0003-2416-4395
Jennifer StuartMerck & Co., Inc., Rahway, NJ, USA.ORCID http://orcid.org/0000-0003-2718-8827
Chethan RamamurthyMerck & Co., Inc., Rahway, NJ, USA.ORCID https://orcid.org/0000-0003-3935-9638
Haojie LiMerck & Co., Inc., Rahway, NJ, USA.
Ronac MamtaniDivision of Hematology and Oncology, Hospitals of the University of Pennsylvania-Penn Presbyterian, Philadelphia, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42262639
PMCPMC13575032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.